Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Skye Bioscience, Inc. (NASDAQ:SKYE) has received an average recommendation of “Moderate Buy” from the eight ratings firms that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $9.80.

Several research analysts have weighed in on SKYE shares. Weiss Ratings restated a “sell (e+)” rating on shares of Skye Bioscience in a research note on Monday, December 29th. Craig Hallum downgraded shares of Skye Bioscience from a “buy” rating to a “hold” rating and set a $2.00 target price on the stock. in a report on Monday, October 6th. Cantor Fitzgerald cut shares of Skye Bioscience from an “overweight” rating to a “neutral” rating and set a $2.00 target price for the company. in a research note on Monday, October 6th. Citigroup reiterated a “market outperform” rating on shares of Skye Bioscience in a research note on Monday, January 5th. Finally, HC Wainwright initiated coverage on shares of Skye Bioscience in a report on Tuesday, September 30th. They set a “buy” rating and a $20.00 price objective for the company.

Key Stories Impacting Skye Bioscience

Here are the key news stories impacting Skye Bioscience this week:

• Neutral Sentiment: News coverage noted a recent intraday decline in SKYE shares (reports of a ~5.9% drop), underscoring short‑term volatility in the stock. Skye Bioscience (NASDAQ:SKYE) Stock Price Down 5.9% – Here’s What Happened
• Negative Sentiment: Rosen Law Firm issued a deadline notice reminding purchasers of SKYE of the Jan. 16, 2026 lead‑plaintiff deadline for the class action covering Nov. 4, 2024–Oct. 3, 2025 — signaling active litigation and potential claim aggregation. SKYE Deadline: SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit
• Negative Sentiment: Faruqi & Faruqi, LLP is investigating claims and urging investors who purchased SKYE during the class period to contact the firm before the Jan. 16 deadline — another sign of competing counsel and ongoing litigation momentum. INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience
• Negative Sentiment: Several other national plaintiffs’ firms (Schall Law Firm, Berger Montague, Bragar Eagel & Squire, The Gross Law Firm) have issued similar notices seeking lead plaintiffs — indicating widespread lawyer solicitation and reinforcing litigation overhang. Representative notices and reminders are linked below. SKYE DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important January 16 Deadline
• Negative Sentiment: Schall Law Firm reminder about the class action and the Jan. 16 deadline — another indicator that the case is active and that settlements or rulings could materially affect shareholder value. SKYE Investors Have Opportunity to Lead Skye Bioscience Inc Securities Fraud Lawsuit with the Schall Law Firm
• Negative Sentiment: Berger Montague and Bragar Eagel & Squire issued final‑deadline alerts to shareholders — these firm notices often precede consolidation of lead counsel and increased litigation activity (discovery, motions), which can pressure the stock. DEADLINE TOMORROW: Berger Montague Advises Skye Bioscience Inc. Investors to Inquire
• Negative Sentiment: The Gross Law Firm and related outlets have been advising shareholders who lost money to contact counsel about the pending class action — continued publicity can sustain negative sentiment and trading volatility. SKYE BIOSCIENCE FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Skye Bioscience Inc Stockholders

Institutional Trading of Skye Bioscience

Several hedge funds have recently modified their holdings of SKYE. Capital Advisors Inc. OK purchased a new position in shares of Skye Bioscience in the third quarter valued at $39,000. Y Intercept Hong Kong Ltd purchased a new stake in Skye Bioscience during the second quarter valued at $42,000. Millington Financial Advisors LLC bought a new position in Skye Bioscience during the second quarter valued at $44,000. Tower Research Capital LLC TRC grew its stake in shares of Skye Bioscience by 121.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 10,927 shares of the company’s stock worth $46,000 after buying an additional 5,989 shares in the last quarter. Finally, Dimensional Fund Advisors LP bought a new stake in shares of Skye Bioscience in the 3rd quarter worth about $53,000. 21.09% of the stock is owned by hedge funds and other institutional investors.

Skye Bioscience Stock Up 3.9%

NASDAQ:SKYE opened at $1.00 on Monday. The business’s 50-day simple moving average is $1.10 and its two-hundred day simple moving average is $2.46. Skye Bioscience has a 52 week low of $0.68 and a 52 week high of $5.75. The stock has a market cap of $32.06 million, a PE ratio of -0.78 and a beta of 2.68.

Skye Bioscience (NASDAQ:SKYE) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.01. Sell-side analysts anticipate that Skye Bioscience will post -1.04 earnings per share for the current fiscal year.

About Skye Bioscience

Skye Bioscience, Inc is a clinical-stage biotechnology company focused on the development of novel, selective cannabinoid type 1 (CB1) receptor modulators for the treatment of ocular diseases. Headquartered in Sunnyvale, California, Skye Bioscience leverages proprietary chemistry and formulation expertise to design and optimize compounds with high potency, tissue selectivity and favorable drug-like properties. The company’s lead product candidate is being evaluated for the treatment of glaucoma and other ophthalmic conditions characterized by elevated intraocular pressure.

Skye Bioscience’s pipeline centers on synthetic cannabinoids engineered to avoid central nervous system side effects commonly associated with traditional cannabinoid therapies.